New Jersey Lawyer & Attorney : Stark & Stark Law Firm : New Jersey Law Blog

The NuvaRing® Mass Tort is presided over by Judge Brian R. Martinotti, in the New Jersey Superior Court - Bergen County. Previously, counsel for both plaintiffs and defendants had chosen ten initial bellwether cases for case specific discovery and trial. On, March 3, 2010, Judge Martinotti held a Case Management Conference. During that conference, Judge Martinotti determined that the discovery deadline on the initial bellwether cases would be March 15, 2011, culminating in proposed trial dates some time in May 2011. 
 

As we have discussed in previous posts, studies have shown that the ingredients contained in the birth control product NuvaRing® have been linked to various forms of severe side-effects including: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage, myocardial infarction and pulmonary embolism.
 

At Stark & Stark we pursue claims throughout the nation against drug manufacturers, so they can be held accountable when the drugs they market are proven to be defective or cause catastrophic injury to the people who use them. Contact Stark & Stark to speak with one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of NuvaRing®.

• Email This
• Print
• Comments
• Trackbacks

As we have discussed in previous posts, pending lawsuits against the manufacturers of NuvaRing®, state that the birth control product has led to severe side-effects such as: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage, myocardial infarction and pulmonary embolism.
 

Courts in the United States have consolidated the NuvaRing® lawsuits on both the State (Mass Tort) and federal (MultiDistrict Litigation or “MDL”) levels. The Mass Tort is presided over by Judge Brian R. Martinotti, in the New Jersey Superior Court - Bergen County. The MDL is presided over by Judge Rodney W. Sippel, in the United States District Court - Eastern District of Missouri. Both judges often collaborate in an effort to assimilate the cases pending in each court. In fact, during the March 3, 2010, Mass Tort case management conference, Judge Martinotti adopted an order recently entered by Judge Sippel, which will permit counsel to coordinate discovery in all cases pending in both the Mass Tort and MDL.
 

If you, or someone you know, has been injured as a result of taking NuvaRing® contact Stark & Stark’s Mass Tort/Pharmaceutical Litigation Team to speak with one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of NuvaRing®.

• Email This
• Print
• Comments
• Trackbacks

As we have discussed in previous posts, studies have shown that the ingredients contained in the birth control products YAZ®, Yasmin® and Ocella® have been linked to various forms of severe side-effects. Reportedly, these side-effects include: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage (including gallbladder damage), myocardial infarction and pulmonary embolism.
 

On February 9, 2010, the New Jersey State Supreme Court granted Mass Tort designation to YAZ®, Yasmin® and Ocella® cases, pursuant to the application made under Rule 4:38A. Accordingly, all pending and future New Jersey state court actions arising out of the use of the oral contraceptives YAZ®, Yasmin® and Ocella® are designated as a mass tort for centralized case management purposes. Any and all such complaints that have been filed in the various counties and that are under or are awaiting case management and/or discovery shall be transferred from the county of venue to Superior Court, Law Division, Bergen County, and assigned to Judge Brian R. Martinotti, J.S.C.
 

If you, or someone you know, has been injured as a result of taking these medications, contact Stark & Stark’s Mass Tort/Pharmaceutical Litigation Team. At Stark & Stark we pursue claims throughout the nation against drug manufacturers, so they can be held accountable when the drugs they market are proven to be defective or cause catastrophic injury to the people who use them. Contact Stark & Stark to speak with one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the YAZ®, Yasmin® or Ocella® manufacturers.

• Email This
• Print
• Comments
• Trackbacks

A large number of claims against the makers of defective birth control products, YAZ®, Yasmin® and Ocella®, for injuries ranging from internal organ damage to deep vein thrombosis have been designated as Mass Tort cases in state court, to be consolidated for case management and discovery purposes before Judge Moss in Philadelphia County, Pennsylvania. In the Mass Tort, counsel recently argued before Judge Moss regarding discovery issues. 

Defendants seek information on Plaintiffs’ use of any forms of contraceptive devices or medications.  Plaintiffs object to providing such information, as it would force minor Plaintiffs to reveal their sexual history, thus discouraging Plaintiffs from proceeding with litigation. Plaintiffs also argue information, such as the use of condoms, is not relevant to the injuries suffered allegedly from the use of YAZ®, Yasmin® and Ocella®.  Those discovery issues remain to be decided.

If you, or someone you know, has suffered injuries as a result of taking YAZ®, Yasmin® or Ocella®) contact one of Stark & Stark’s Mass Tort Attorneys today for a free case review.

• Email This
• Print
• Comments
• Trackbacks

Plaintiffs have brought claims against the makers of YAZ®, Yasmin® and Ocella®, for injuries ranging from internal organ damage (including gallbladder damage), to deep vein thrombosis (or blood clots), stroke, heart attack, myocardial infarction and pulmonary embolism.

A large number of such cases have been designated as Multidistrict Litigation (MDL) cases in the federal courts, to be consolidated for case management and discovery purposes before Judge Herndon the United States District Court for the Southern District of Illinois. In the MDL, on November 12, 2009, the Court appointed attorneys to act as Defendants’ Lead and Liason Counsel, as well as Plaintiffs’ Steering Committee. These select attorneys will be primarily responsible for conducting litigation activities for the consolidated cases.

Stark & Stark’s Mass Tort/Pharmaceutical Litigation Team pursues claims throughout the nation against drug manufacturers, so they can be held accountable when the drugs they market are proven to be defective. If you feel you, or someone you know, have experienced any side-effects from taking YAZ® or Yasmin® contact Stark & Stark to speak to one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the YAZ®, Yasmin® or Ocella® manufacturers.

• Email This
• Print
• Comments
• Trackbacks

As we have discussed in previous posts, studies have shown that the ingredients contained in YAZ®, Yasmin® and Ocella® have been linked to various forms of severe side-effects. Reportedly, these side-effects include: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage (including gallbladder damage), myocardial infarction and pulmonary embolism. Recently, a large number of YAZ® lawsuits have been designated as Mass Tort or Multidistrict Litigation (MDL) cases.

Studies show that one of the more serious YAZ® side effects, Yasmin® and Ocella® use is Deep Vein Thrombosis, which is commonly known as DVT. DVT is a condition characterized by the presence of a blood clot in a vein, usually in the legs or pelvis. DVT does not always show symptoms, but may cause swelling and pain in the affected extremities. If the blood clot dislodges and travels to the lungs, it may cause a Pulmonary Embolism - this potentially fatal condition is commonly known as a PE. Studies also show that DVT and PE sufferers have a heightened risk of long-term complications and multiple DVT and PE episodes, which can, in turn, lead to the need for continuing treatment. Further, DVT and PE sufferers have a much higher incidence of arterial thrombosis, heart attack and stroke.

Stark & Stark’s Mass Tort/Pharmaceutical Litigation Team pursues claims throughout the nation against drug manufacturers, so they can be held accountable when the drugs they market are proven to be defective or cause catastrophic injury to the people who use them. If you feel you have experienced any side-effects from taking YAZ® or Yasmin® (or the generic brand, Ocella®), you can contact Stark & Stark and speak to one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the YAZ®, Yasmin® or Ocella® manufacturers.

• Email This
• Print
• Comments
• Trackbacks

As we have discussed in previous posts, studies have shown that the ingredients contained in YAZ®, Yasmin® and Ocella® have been linked to various forms of severe Yaz side-effects. Reportedly, these side-effects include: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage (including gallbladder damage), myocardial infarction and pulmonary embolism. Recently, a large number of YAZ®, Yasmin® and Ocella® cases have been designated as Mass Tort or Multidistrict Litigation (MDL) cases.

The New Jersey State Courts are currently contemplating granting Mass Tort designation to YAZ®, Yasmin® and Ocella® cases currently pending in New Jersey. The makers of YAZ®, Bayer Healthcare Pharmaceuticals, are headquartered in Wayne, New Jersey. The makers of Ocella®, Barr Pharmaceuticals, are headquartered in Montvale, New Jersey. Similar cases have received MDL treatment in the United States District Court for the Southern District of Illinois, and Mass Tort treatment in Philadelphia County, Pennsylvania. The New Jersey Mass Tort would eventually be venued in Atlantic, Bergen or Middlesex counties. 

• Email This
• Print
• Comments
• Trackbacks

Since the beginning of October 2009, over 350 YAZ®, Yasmin® and Ocella® cases from various jurisdictions throughout the country have been transferred to the MDL in the United States District Court for the Southern District of Illinois. On November 9, 2009, motions were filed to appoint Plaintiffs’ lead counsel and a Plaintiffs’ Steering Committee. The Court will hold a conference in the coming weeks to address the newly transferred cases and pending motions.

Stark & Stark’s Mass Tort/Pharmaceutical Litigation Team pursues claims throughout the nation against drug manufacturers, so they can be held accountable when the drugs they market are proven to be defective or cause catastrophic injury to the people who use them. If you feel you have experienced any side-effects from taking YAZ® or Yasmin® (or the generic brand, Ocella®), you can contact Stark & Stark and speak to one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the YAZ®, Yasmin® or Ocella® manufacturers.

• Email This
• Print
• Comments
• Trackbacks

Studies have shown that the ingredients contained in YAZ®, Yasmin® and Ocella® (including the synthetic progestin, drospirenone), have been linked to various forms of internal organ damage (including gallbladder damage), as well as deep vein thrombosis, or blood clots. These blood clots can form in the deep veins of the legs, pelvis, or arms causing extreme pain. It has been found that if the clot dislodges it can lead to sudden, and many times fatal, stroke, heart attack, myocardial infarction or pulmonary embolism.

Within the past month, a large number of cases against Bayer HealthCare Pharmaceuticals, the manufacturers of YAZ® and Yasmin®, have been designated as Mass Tort or Multidistrict Litigation (MDL) cases. Mass Tort cases (in State courts) and MDL’s (in federal courts) are methods of organizing and managing cases involving the same or similar injuries and common defendants, in an expedient, cost-effective manner that better enables the plaintiffs to pursue their claims. The Mass Tort cases will be consolidated for case management and discovery purposes before Judge Moss in Philadelphia County, Pennsylvania. The MDL cases will be consolidated for case management and discovery purposes before the Judge Herndon the United States District Court for the Southern District of Illinois.

Stark & Stark’s Mass Tort/Pharmaceutical Litigation Team pursues claims throughout the nation against drug manufacturers, so they can be held accountable when the drugs they market are proven to be defective or cause catastrophic injury to the people who use them. If you feel you have experienced any side-effects from taking YAZ® or Yasmin® (or the generic brand, Ocella®, which is marketed and distributed by Barr Laboratories), you can contact Stark & Stark and speak to one of the Mass Tort/ Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the YAZ®, Yasmin® or Ocella® manufacturers.

• Email This
• Print
• Comments
• Trackbacks

As we have discussed in previous posts, NuvaRing®, the combined contraceptive vaginal ring that is supposed to provide month-long birth control, is currently involved in a Multi-District Litigation (“MDL”) in the United States District Court for the Eastern District of Missouri.

Recently, defendants filed numerous motions to dismiss certain plaintiff’s claims for failure to provide a timely or complete “Plaintiff Fact Sheet” (also known as a “PFS”). In pharmaceutical cases with Mass Tort or Multi-District Litigation designations, plaintiffs are required to submit a detailed PFS. The PFS requires the plaintiff to supply medical, liability and general background information within a specified time period, usually subject to periodic updating and revision. The PFS is instrumental in permitting both parties, as well as the Court, to choose bellwether cases for case specific discovery and trial. While defendants’ counsel invariably submit that a broad PFS is especially crucial to determine the defenses to a particular plaintiff’s claims, plaintiffs’ counsel must make certain that the PFS is sufficiently circumscribed so as not to be particularly burdensome to the plaintiffs. Accordingly, there is a constant tension between the parties as to the timing and content of the PFS’s, usually culminating in similar protracted motion practice throughout the litigation.

• Email This
• Print
• Comments
• Trackbacks